(Q44544276)

English

Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial

scientific article published on 21 June 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial (English)

1 reference

Europe PubMed Central

4 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Glossmann JP

1

1 reference

Europe PubMed Central

4 December 2017

Engert A

2

1 reference

Europe PubMed Central

4 December 2017

Wassmer G

3

1 reference

Europe PubMed Central

4 December 2017

Flechtner H

4

1 reference

Europe PubMed Central

4 December 2017

Ko Y

5

1 reference

Europe PubMed Central

4 December 2017

Rudolph C

6

1 reference

Europe PubMed Central

4 December 2017

Metzner B

7

1 reference

Europe PubMed Central

4 December 2017

Dörken B

8

1 reference

Europe PubMed Central

4 December 2017

Wiedenmann S

9

1 reference

Europe PubMed Central

4 December 2017

Diehl V

10

1 reference

Europe PubMed Central

4 December 2017

Josting A

11

1 reference

Europe PubMed Central

4 December 2017

publication date

21 June 2003

1 reference

Europe PubMed Central

4 December 2017

Annals of Hematology

1 reference

Europe PubMed Central

4 December 2017

82

1 reference

Europe PubMed Central

4 December 2017

8

1 reference

Europe PubMed Central

4 December 2017

469-475

1 reference

Europe PubMed Central

4 December 2017

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Evaluation of experiments with adaptive interim analyses.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Erythropoiesis and erythropoietin in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Biological basis of anemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Cost of outpatient blood transfusion in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Transfusion requirements, risks, and costs for patients with malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Costs of blood transfusion: a process-flow analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Proinflammatory cytokines lowering erythropoietin production

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

The Use of Erythropoietin in Radiation Oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Effect of recombinant human erythropoietin after allogenic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-003-0695-0

21 January 2018

Identifiers

10.1007/S00277-003-0695-0

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44544276&oldid=2027250333"